Pics 6: Lymphoid/PCD Flashcards

1
Q

HL subtypes and frequency of each

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Difference between cHL and NLPHL
New name for NLPHL

A

NLPBCL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Early stage HL: prognostic markers
GHSG vs EORTC

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Prognostic in Advanced stage cHL

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

PET Deauville scores

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Early stage cHL, favourable
4 options, which trials

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Early stage HL, unfavourable
4 options, trials

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Advanced stage cHL
2 main options in 2024
What were the prior 3 options

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

HL conclusions 1

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

HL early stage conclusions

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

HL advanced stage conclusions, R/R

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

New therapies in HL, conclusions

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

WM/LPL DDX

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Special toxicities of drugs used in WM
Ritux
Flu/Clad
Benda
Bortez
Ibrutinib

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

1L treatment of WM
2nd line
MAG neuropathy
Bing Neel
Intolerant or refractory to Ibrutinib

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

AL amyloid staging tests

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

AL amyloid algorithm for workup

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

AL amyloid AutoSCT transplant eligibility

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

AL amyloid treatment approach

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

POEMS diagnostic criteria

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Natural history of MM

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

MGUS risk stratification, risk groups, recommended monitoring

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

IMWG criteria for MGUS/SMM/MM

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

MGRS types
Glomerular vs Tuuloisterstitial vs vascular
Which 2 types deposit everywhere?

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

SMM what is the 20-20-20 rule?
Risks of progression

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

R-ISS for MM

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

MM treatment paradigm, phases of therapy for Fit vs Unfit/not Auto

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Approved therapies in MM over the years

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

IMWG response criteria for MM

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

R/R MM definition

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Backbones of therapy for MM early relapse

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Plasmacytoma evaluation and therapy algorithm

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Solitary plasmacytoma diagnostic criteria
Solitary bone
Solitary extra medullary
Solitary with minimal marrow involvement
MM

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Plasma cell dyscrasia summary slide

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Deauville scale for PET uptake

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Risk factors for early stage HL
EORTC or GHSG

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

CVD incidence in HL survivors for RT or anthracycline

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Frontline chemo regimens in HL
What drugs are in:
A-AVD
ABVD
escBEACOPP

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Longterm followup for HL survivors

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

MM pathology images

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

DDX of monoclonal gammopathies table

A
38
Q

MGUS: factors that influence risk of progression

A
38
Q

Uncommon and rare plasma cell disorders

A
38
Q

SMM risk factors for progression

A
39
Q

Symptoms in MM and pathophys

A
40
Q

Prognostic factors in MM
8 tumor related
5 host related

A
41
Q

IMWG 2016 relapse definition

A
41
Q

R-ISS staging for MM

A
41
Q

IMWG response criteria for MM, complicated table

A
42
Q

Drug classes and examples in MM

A
42
Q

R/R MM regimens and trials

A
43
Q

Dose levels, modifications for frailty, meds in MM
Bortez, Len, Dex, Melph, Fred, Cyclophos

A
44
Q

Organ involvement in Amyloid, characteristics of each

A
45
Q

Hematologic response criteria in amyloid

A
46
Q

Organ response criteria in amyloid

A
47
Q

Cell of origin for B cell NHLs

A
48
Q

Lugano criteria staging for NHL

A
49
Q

GELF criteria for high tumor burden, when to treat

A
50
Q

FLIPI scoring parameters

A
51
Q

FL progression/transformation slide
RFs for transformation

A
52
Q

MALT lymphoma, antigen triggers and which MALT lymphoma?
What translocation to predict resistance of lymphoma to H pylori eradication

A
53
Q

FL relapses, treatment strategies at each time

A
54
Q

Mantle cell treatment overview
Fit/young vs old/unfit

A
55
Q

Summary slide: indolent lymphomas and mantle cell

A
56
Q

IHC/Flow markers and lineages

A
57
Q

B cell development, and which malignancies from which cell of origin

A
58
Q

RFs for NHL

A
58
Q

T cell development and associated neoplasms

A
58
Q

Phenotypic markers for different lymphomas

A
59
Q

DLBCL IPI in rituximab era
Which RFs?

A

APLES
Age>60
PS 2+
LDH
>1 extra nodal site
Stage 3/4

59
Q

Lugano staging system table

A
60
Q

FLIPI Score

A

NO-LASH

61
Q

MIPI score

A

Age
PS
LDH
WBC count

62
Q

Approach to ND FL patient, by tumor burden and symptoms

A
63
Q

GELF criteria for high tumor burden

A
64
Q

iwCLL indications to treat CLL

A
65
Q

CLL-IPI

A
66
Q

Frontline BTKi vs Ven+O pros/cons

A
67
Q

CLL conclusion slide

A
68
Q

Chronic B cell LPDs, immunophenotypes

A
69
Q

CLL staging:
Stage, Binet, Rai

A
70
Q

BCR signalling in CLL, drugs used and their targets

A
71
Q

CLL-IPI table

A
72
Q

Treatment algorithm for previously untreated CLL

A
73
Q

Indications for starting therapy in CLL, and precautions table

A
74
Q

PTCL types by presentation
Leukemic
Nodal
Other extra nodal

A
75
Q

Survival by different TCLs
Common vs Uncommon
Best vs worst

A
76
Q

PTCL initial management

A
77
Q

ATLL approach by subtype
4 subtypes

A
78
Q

Mgmt cutaneous TCL
early vs advanced stages

A
79
Q

IPI for DLBCL

A
80
Q

Rituximab MOA
What types of cell killing?
Risks of Ritux

A
80
Q

DLBCL frontline treatment summary

A
81
Q

RCHOP in DLBCL
Drugs and dosages
How long is a cycle?
Common toxicities

A
82
Q

Polatuzumab
MOA
What indications?

A

DLBCL untreated
DLBCL r/r

83
Q

CAR-T vs ASCT in DLBCL
Trials, and which drugs

A
84
Q

R/R DLBCL
Guide to picking next therapy
R/R >/< 12 mo
prior ASCT
prior CART
ineligible for ASCT/CART

A
85
Q

3 types of Burkitt Lymphoma, and characteristics
Who, where, EBV status?

A
86
Q

Burkitt teaching points slide

A
87
Q

Aggressive B cell lymphoma survivorship/followup

A